Costimulatory wars: The tumor menace

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 589-596

  Hurwitz, Arthur A ^a   Kwon, Eugene D ^b   Van Elsas, Andrea ^c  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

CANCER IMMUNOTHERAPY; HUMAN; IMMUNOMODULATION; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR;

EID: 0033822222     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00147-3     Document Type: Review

References (73)

1. A theory of self-nonself discrimination
2. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
3. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells
4. T cell co-stimulatory molecules other than CD28
5. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
6. Costimulatory regulation of T cell function
7. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
8. CTLA-4 can function as a negative regulator of T cell activation
9. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
10. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
11. Protective immunity to nematode infection is induced by CTLA-4 blockade
12. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
13. CTLA-4 is required for the induction of high dose oral tolerance
14. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
15. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28
16. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
17. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion
18. Ochs HD: B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells
19. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
20. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
21. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
22. Manipulation of costimulatory signals to enhance antitumor T cell responses
23. A reassessment of the role of B7-1 expression in tumor rejection
24. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity
25. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
26. Enhancement of the anti-tumor immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma
27. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice
28. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway
29. Potent activity of soluble B7-1gG fusion proteins in therapy of established tumors and as vaccine adjuvant
30. Enhancement of antitumor immunity by CTLA-4 blockade
31. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
32. Enhanced induction of antltumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
33. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
34. Manipulation of T cell cell activation in the anti-tumor immune response
35. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
36. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
37. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
38. Vaccination with a recombinant vaccinia virus encoding 'self' antigen induces autimmune vitiligo and tumor cell destruction in mice requirement for CD4+ T lymphocytes
39. Tumor immunity and autoimmunity induced by immunization with homologous DNA
40. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
41. Inducing autoimmune disease to treat cancer
42. Induction of CTL responses by simultaneous administration of liposomal pepfide vaccine with anti-CD40 and anti-CTLA-4 mAb
43. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
44. The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells
45. CD4 T cell traffic control: In vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles
46. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells
47. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and heed and neck cancers
48. Engagement of the OX-40 receptor in vivo enhances antitumor immunity
49. Analysis of 4-1 BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
50. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
51. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 costimulatory pathway
52. NKI.1 cells express 4-1 B B (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
53. Antitumor responses induced by transgenic expression of CD40 ligand
54. Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7
55. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells
56. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge
57. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
58. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosls and suppresses in vivo tumor formation via gene transfer
59. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
60. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
61. T-cell co-stimulation through BTRP-1 and ICOS
62. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF alpha
63. Identification of GL50, a novel B7-1ike protein that functionally binds to ICOS receptor
64. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
65. Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
66. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
67. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
68. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
69. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
70. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
71. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism
72. The role of CTLA-4 in tolerance induction and antigen administration cell differentiation in experimental autoimmune encephalomyelitis: i.v. antigen administration
73. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells